Seroprevalence and Risk of Cytomegalovirus Transmission in Blood Donors: Implications for Transfusion Safety
Keywords:
Cytomegalovirus (CMV), Seroprevalence, Blood transfusion, Leukoreduction, CMV-DNAAbstract
Introduction: Transmission of cytomegalovirus (TT-CMV) represents a potential risk in blood transfusions, even when preventive measures such as the use of leukoreduced blood components are implemented. Objective: The purpose of this study was to evaluate the seroprevalence of IgG-CMV and to examine the relationship between seropositivity and the presence of CMV-DNA as an indicator of active infection. Material and Method: A cross-sectional seroepidemiological study was carried out in 2,953 donor samples. Anti-IgG-CMV was measured using the DiaMEDIC ELISA assay, classifying the results as positive, indeterminate, and negative. Subsequently, the number of samples in each group was determined, and the real-time PCR test (ROCHE) was performed on 466 samples, following the manufacturer's specifications. Results: The seroprevalence of anti-CMV IgG was 97.7%, while 1.7% of samples (n: 8) were positive for CMV DNA, of which six were classified as positive and two as indeterminate according to serological analysis. Discussion: A high seroprevalence of CMV was observed in asymptomatic blood donors, but no correlation was found between serological and molecular results. This may be attributed to the latent state of the virus and the low amount of plasma DNA present. However, eight CMV DNA-positive donors were identified, suggesting the possibility of active infection or re-infection. References: Appropriate references should be included for the studies or sources you have cited in the text. Be sure to follow the Vancouver or APA citation guidelines as directed by your publication.
References
1. Agut H, Bonnafous P, Gautheret-Dejean A. Laboratory and clinical aspects of human herpesvirus 6 infections. Clin Microbiol Rev. 2015;28(2):313-335. doi:10.1128/CMR.00122-14
2. Bawa MK, Mamman A, Olayinka A, Gidado S, Waziri NE, Balogun MS, et al. Blood donor safety, prevalence and associated factors for cytomegalovirus infection among blood donors in Minna-Nigeria, 2014. Pan Afr Med J. 2019;32(Suppl 1):6. doi:10.11604/pamj.supp.2019.32.1.13297
3. Das B, Kaur G, Basu S. Seroprevalence of cytomegalovirus antibodies among blood donors and multitransfused recipients—a study from north India. Transfus Apher Sci. 2014;50(3):438-442. doi:10.1016/j.transci.2014.02.022
4. Díaz J, Henao J, Rodelo J, García A, Arbeláez M, Jaimes F. Incidence and risk factors for cytomegalovirus disease in a Colombian cohort of kidney transplant recipients. Transplant Proc. 2014;46(1):160-166. doi:10.1016/j.transproceed.2013.07.070
5. Furui Y, Satake M, Hoshi Y, Uchida S, Suzuki K, Tadokoro K, et al. Cytomegalovirus seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors. Transfusion. 2013;53(10):2190-2197. doi:10.1111/trf.12390
6. Josephson CD, Castillejo MI, Caliendo AM, Waller EK, Zimring J, Easley KA, et al. Prevention of transfusion-transmitted cytomegalovirus in low-birth weight infants (≤1500 g) using cytomegalovirus-seronegative and leukoreduced transfusions. Transfus Med Rev. 2011;25(2):125-132. doi:10.1016/j.tmrv.2010.11.004
7. Kowalzik F, Hitzler W, Runkel S, Marron M. Seroprevalence and seroconversion of cytomegalovirus in a large group of healthy German blood donors: potential contribution to transfusion transmitted infections. Clin Lab. 2020;66(4). doi:10.7754/Clin.Lab.2019.190901
8. Lancini D, Faddy HM, Flower R, Hogan C. Cytomegalovirus disease in immunocompetent adults. Med J Aust. 2016;201(10):578-580. doi:10.5694/mja14.00183
9. Lancini DV, Faddy HM, Ismay S, Chesneau S, Hogan C, Flower RL. Cytomegalovirus in Australian blood donors: seroepidemiology and seronegative red blood cell component inventories. Transfusion. 2016;56(6 Pt 2):1616-1621. doi:10.1111/trf.13459
10. Mengjiao L, Yushan X, Yan L, Dawei C, Xiaojun Z, Yongjun W, et al. Prevalence of transfusion-transmitted infections in hospitalized patients before transfusion and volunteer blood donors in Zhejiang Province, China. Infect Dis Now. 2024;54(2):104861. doi:10.1016/j.idnow.2024.104861
11. Shaiegan M, Rasouli M, Zadsar M, Zolfaghari S. Meta-analysis of cytomegalovirus seroprevalence in volunteer blood donors and healthy subjects in Iran from 1992 to 2013. Iran J Basic Med Sci. 2015;18(7):627-634. PMID:26351551; PMCID:PMC4556753
12. Tuon FF, Wollmann LC, Pegoraro D, Gouveia AM, Andrejow AP, Schultz AT, et al. Seroprevalence of Toxoplasma gondii, cytomegalovirus and Epstein Barr virus in tissue donors in Brazil. J Infect Public Health. 2019;12(2):289-291. doi:10.1016/j.jiph.2018.07.001
13. Ziemann M, Hennig H. Prevention of transfusion-transmitted cytomegalovirus infections: which is the optimal strategy? Transfus Med Hemother. 2014;41(1):40-44. doi:10.1159/000357102
14. Ziemann M, Juhl D, Görg S, Hennig H. The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients. Transfusion. 2013;53(10):2183-2189. doi:10.1111/trf.12199
15. Ziemann M, Krueger S, Maier AB, Unmack A, Goerg S, Hennig H. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion. 2007;47(11):1972-1983. doi:10.1111/j.1537-2995.2007.01420.x
16. Ziemann M, Thiele T. Transfusion-transmitted CMV infection—current knowledge and future perspectives. Transfus Med. 2017;27(4):238-248. doi:10.1111/tme.12437
17. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwe B, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019;29(3):e2034. doi:10.1002/rmv.2034
18. de la Mora L, Mallolas J, Ambrosioni J. Epidemiología, tratamiento y pronóstico de la infección VIH en 2024: revisión práctica. Med Clin. 2024:535-541. doi:10.1016/j.medcli.2023.12.007
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Sapiens in Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in this journal are available under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. This licence authorises third parties to download, copy, distribute, adapt and reuse the contents, including for commercial purposes, provided that credit is given to the original author of the work.
